Journal
CELL
Volume 168, Issue 4, Pages 724-740Publisher
CELL PRESS
DOI: 10.1016/j.cell.2017.01.016
Keywords
-
Categories
Funding
- NIH [P50GM081879, R01 CA196277, 5R01CA120409]
- Parker Institute for Cancer Immunotherapy
- Howard Hughes Medical Institute
Ask authors/readers for more resources
Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can serve as a powerful new class of cancer therapeutics. Clinical experience has helped to define the major challenges that must be met to make engineered T cells a reliable, safe, and effective platform that can be deployed against a broad range of tumors. The emergence of synthetic biology approaches for cellular engineering is providing us with a broadly expanded set of tools for programming immune cells. We discuss how these tools could be used to design the next generation of smart T cell precision therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available